SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Venus Remedies gets nod from UK, New Zealand for antibiotic drug

16 Nov 2011 Evaluate

Drug firm Venus Remedies has received approvals from health authorities in the UK and New Zealand for marketing its generic injectable antibiotic Meropenem which is used for treating bacterial infections. The company has received approvals from Medicines and Healthcare products Regulatory Agency (MHRA) UK and New Zealand Ministry of Health for its generic Meropenem.

The drug will be launched in this fiscal year. Meropenem sales account for USD 906 million across the globe, which is estimated to grow to USD 1,006 million by 2012. The company is already selling the drug in various markets and is in the process of extending its sales in other regulated markets.

Venus Remedies Share Price

1042.35 3.25 (0.31%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×